Objective: To evaluate the reliability of salivary levels of theophylline in monitoring therapy of apnoea of prematurity.
Introduction
Intravenous and oral theophylline has long been the mainstay of the treatment and prevention of apnoea in neonates. Theophylline is an effective drug but a high serum concentration has the potential to cause serious side effects, including seizures, cardiac arrhythmias and death. 1, 2 Theophylline dosing in infants has not been well defined. 3, 4 Small infants have a decreased capacity to metabolize theophylline and the metabolic path is different from that in older children and adults. Some authors demonstrated that a variability of metabolism and subsequently of serum concentration of theophylline correlated with postconceptional age (PCA) of neonates. 5 Therefore, it is compulsory to measure serum levels for monitoring the treatment of apnoea of prematurity. However, measuring the salivary level of theophylline is a potentially useful alternative to serum level, because sampling saliva is less invasive. 6 There are data in the literature consistent with the reliability of salivary theophylline concentration for estimation of serum concentration, but most of the studies were performed in older children or adults with asthma. Only a few studies have been conducted in premature infants and the results are not satisfactory. [7] [8] [9] The purpose of this study was to evaluate the correlation between serum and saliva concentration of theophylline in infants with apnoea of prematurity. A secondary variable studied was the influence of PCA on theophylline metabolism.
Methods

Patients
The study group included newborn infants according to the following criteria: (a) gestational age <36 weeks; (b) episodes of apnoea that lasted at least 20 s and (c) episodes of apnoea <20 s accompanied by cyanosis and/or bradycardia. Exclusion criteria were as follows: (a) any congenital abnormality; (b) infection (sepsis confirmed by blood culture); (c) neurological disorders; (d) severe hepatic diseases; (e) renal diseases and (f) concomittent medication that might interfere with theophylline metabolism. Thirteen infants aged between 2 and 10 weeks underwent the study. All parents were informed of the nature of the study and written consent was obtained. The study protocol was approved by the ethics committee.
Treatment with theophylline
We used ampoules of aminophylline (85% theophylline) containing 240 mg/10 ml Miofilin 2.4% (Terapia SA, Cluj-Napoca). A loading dose of 5 mg/kg of aminophylline was administered intravenously (i.v.) over 10-min period, followed by maintenance doses of 3 mg/kg given every 8 h for the next days. The mean duration of therapy was 15 days and the outcome was good in all cases.
Blood and saliva collection Blood and saliva samples were obtained simultaneously at 2 and 4 h after the loading dose. During the next 2 days, simultaneous samples were collected before the maintenance dose and at 4 h after the administration of aminophylline. Venous blood (1-2 ml) was collected from an arm different from the one in which theophylline was administered. For the stimulation of mixed saliva secretion, we placed citric acid crystals (1-2 mg) on the tongue. Approximately 0.5-1 ml of saliva was then collected by aspiration in a sterile recipient. The duration of saliva sampling varied between 10 and 15 min.
Analysis
Serum and saliva samples were kept refrigerated for 48-72 h at À201C before extraction. We measured the concentration of theophylline by isotope dilution mass spectrometry, using as an internal standard theophylline labelled with the 15 N isotope. Analysis in serum and saliva was performed on the molecular ion, m/z ¼ 180 for the natural theophylline and m/z ¼ 181 for the internal standard. This method does not allow interferences between theophylline and caffeine measuring.
Statistics
We calculated the coefficient of correlation and analysed the regression curve, to estimate the correlation between serum and saliva concentration. We calculated the coefficient of variation or relative standard deviation (s.d.) of the ratio between serum and saliva concentration. The Student's t-test was used and P<0.01 was considered as statistically significant.
Results
The study group consisted of 13 premature newborn infants. The infants were divided into two subgroups according to their PCA. Group A consisted of six infants with PCA of 32.8±2.0 weeks (between 30 and 35 weeks) and group B included seven infants with PCA of 37.1±0.8 weeks (between 36 and 38 weeks). Demographic data are presented in Table 1. After obtaining a stable level of theophylline by i.v. loading dose, a total of 78 blood samples were obtained. Saliva was collected simultaneously with blood and 64 samples were obtained. From these saliva samples, seven were excluded because of contamination with blood during collection (from superficial lesions of oral mucosa, probably due to manipulation during collection) or with local debris.
The mean value of the serum concentration was 7.8±5.8 mg/ml (mean±s.d.) varying between 1.6 and 27.9 mg/ml, while salivary concentration was 5.5±4.6 mg/ml.
The ratio between the serum and saliva levels for the 57 paired samples was 1.53±0.28. Calculation of relative s.d, revealed a value of 5.44%, which reflects a small interindividual variation of the ratio. The analysis of the regression curve showed a strong correlation between serum and saliva concentration, with a correlation coefficient of r ¼ 0.973 and a slope of B ¼ 0.6822 ( Figure 1) . We examined the ratio at different intervals after administration of theophylline and it revealed no significant differences. After loading dose, the ratio was 1.43 at 2 h and 1.53 at 4 h. The coefficient of correlation between serum and saliva levels of theophylline was 0.986 and 0.963 at these two intervals. In the second and third days of therapy, the ratio was 1.52 and 1.67 at 8 h after maintenance dose and 1.60 and 1.44, respectively, at 4 h after the dose administration. The coefficient of correlation varied between 0.957 and 0.999 during the second and third days of therapy at different intervals after dose administration.
There were differences of theophylline concentration between the two age groups. In group A, with small PCA, serum concentration of theophylline was 10.6±7.4 mg/ml and saliva concentration was 7.9±5.5 mg/ml. The ratio between serum and saliva levels in 27 paired samples was 1.44±0.22 with a small Salivary theophylline for apnoea of prematurity P Chereches-Panta et al interindividual variation of 6.56%. The correlation between serum and saliva concentration was strong (r ¼ 0.975).
In group B, with higher PCA, the serum concentration of theophylline was 5.3±2.0 mg/ml and saliva concentration was 3.2±1.2 mg/ml. The ratio between serum and saliva levels in 30 paired samples was 1.62±0.31 with a small interindividual variation of 5.22%. The correlation between serum and saliva concentration was strong (r ¼ 0.836). The differences between the two age groups were statistically significant for both serum and saliva theophylline concentration. Regarding the differences between the value of the serum/saliva concentration ratio in the two groups, a significance of P ¼ 0.0155 was found (Table 2) .
Discussion
Theophylline is a major drug in the management of idiopathic apnoea of prematurity. There is a large interpatient variability in dosage requirements due to interpatient variability in theophylline clearance, which also varies with age. The metabolic path in premature infants is different from that in older infants and children. [10] [11] [12] [13] There have been extensive studies of the evaluation of theophylline dosing equations that are useful for this age group. [3] [4] [5] Therefore, close treatment monitoring by serum or saliva is compulsory.
The few data in the literature on the value of saliva concentration in premature infants are still controversial. Khanna et al. 7 reported that saliva levels are reliable for monitoring the therapy with both theophylline and caffeine in premature infants. Three years later, Toback et al. 9 revealed a ratio between serum and saliva of 1.02±0.09, which is smaller than in other studies. They estimated that saliva concentration in premature infants is approximately equal to serum concentration of theophylline. 9 In the study of Aviram et al., 8 the ratio was 1.78±0.22 and the correlation coefficient r ¼ 0.96. These authors included both premature infants and older children with asthma in their study group. 8 The results of our study confirm the strong correlation between serum and saliva levels of theophylline (r ¼ 0.973). Moreover, the small interindividual variation of the serum/saliva concentration ratio would allow the use of saliva concentration multiplied by 1.53 (the value of the ratio) for monitoring the therapy.
In the past 30 years, there have been extensive studies on the value of salivary concentration in monitoring therapy with anticonvulsivant drugs (carbamazepine, phenytoin, phenobarbital, primidone, ethosuximide valproic acid), antibiotics, caffeine, paracetamol and cortisol. 14, 15 The results are variable for each of these drugs. According to the transmembraneous transfer, drugs may be classified into four groups based on their ratio between salivary/serum levels (<1.0, 1 or >1.0) and the pH. 16 The therapy of apnoea of prematurity with caffeine citrate might also be monitored using saliva. 17 The salivary concentration of caffeine predicts its serum level with a good reliability.
One factor that may influence the concentration of theophylline is PCA. Kraus et al. 5 showed that infants with PCA below 40 weeks have a higher risk for achieving toxic levels of theophylline. Our data also revealed significant higher concentration of theophylline in both serum and saliva for infants with smaller PCA. Although we found differences in the ratio between serum and saliva concentration in the two age groups, these differences were not significant (P>0.01).
In conclusion, measuring saliva theophylline concentration is a reliable method for monitoring treatment with theophylline in premature infants with apnoea. This technique is more acceptable than measuring theophylline in serum, because it is painless, simple, less invasive, cheaper and allows multiple sampling during the day. Salivary theophylline for apnoea of prematurity P Chereches-Panta et al
